Immunogenicity Data Drove Monkeypox Dose-Sparring Decision…It Also Drove Initial Approval

Comfort with the initial approval based on inferred effectiveness may have made the current EUA process more palatable to US FDA officials but means there is a bigger gap in what’s known about the vaccine’s effectiveness overall.

white house monkeypox press briefing Aug. 9, 2022
Biden administration officials discuss Jynneos EUA or dose-sparing vaccine strategy 9 August. • Source: White House Press Briefing

More from Vaccines

More from Pink Sheet